What this site is and how it got here

• [dev] Fatal flaw
  Fatal flaw

  Iatrogenic harm risk is structural, not solved: the device's value prop attacks Furbo for rewarding during fear states, but Pawvlov's own ESP32-S3 4-class classifier running at 5fps on novel pose data (no public labeled dataset exists per feas brief) will inevitably misclassify and reward fear states. One viral 'Pawvlov made my dog worse' Reddit thread destroys the entire 'therapy, not toy' positioning the brand is built on — this is a brand-existential risk the founder explicitly created by accusing competitors of the same failure mode.

• [dev] Fatal flaw
  Fatal flaw

  $215K seed is critically underfunded with zero CAC budget: $105K tooling + $45K eng + $12K SAB + $12K FCC + $9K beta + $6K insurance + $4K reserve = $193K committed before any marketing, customer acquisition, founder salary beyond 90 days, working capital for inventory restock, classifier data collection (10K+ labeled frames), or contingency. The fin brief assumes 3.5K Y1 units sold with no documented CAC channel and no marketing line item. Hardware DTC with $0 acquisition budget does not ship 3.5K units.

• [dev] Fatal flaw
  Fatal flaw

  Timeline math is broken: 90-day MVP is contradicted by the feas brief (6-9 month industry norm), 8-12 week tooling, 8-12 week FCC cert, and a non-existent labeled training dataset. Realistic first ship is month 9-12, leaving 0-3 months in Y1 to hit the fin brief's $1M revenue target. Seed funds only ~12 months of opex per fin brief; a 3-month slip burns the entire runway before unit-1 retail.

• [dev] Rebuttal
  Rebuttal · market · medium/high

  TAM ~$2.16B by applying ~$60 annual anxiety-solution spend across the ~36M US dogs with noise anxiety → The $60/year/dog multiplier has no cited source. ThunderShirt is a $40 one-time purchase, Adaptil diffusers are $25-60/year, and trazodone runs $15-40/month for severe cases only (~5-10% of anxious dogs, not 33%). The 33% prevalence figure is owner-reported behavioral observation, not clinical diagnosis — addressable population for a $249 device is materially smaller. Realistic TAM is likely $300-500M, not $2.16B.

• [dev] Rebuttal
  Rebuttal · comp · high/medium

  Moat score of 4 with silent-auger + floor-tray delivery, DACVB SAB endorsement, and 'therapy not toy' brand wedge as defensibility → None of these are durable moats. The silent auger is mechanical engineering, not patentable IP — PETLIBRO/Furbo can replicate in one hardware cycle. SAB endorsements transfer to any well-funded competitor. The 'therapy' brand wedge is an FTC substantiation liability without clinical trials, not a moat. Comp brief admits incumbents could ship anxiety mode in 12-18 months; realistic moat score is 2-3.

• [dev] Rebuttal
  Rebuttal · feas · high/high

  Feasibility score 6 with 90-day MVP buildable using mature off-the-shelf components → The feas brief itself contradicts the score by flagging the 90-day timeline as ~2-3x unrealistic, the labeled dataset as non-existent, the auger spec as aggressive, and the 49% tooling commitment as the dominant capital risk. With four structural unknowns (classifier accuracy, dataset acquisition, auger noise floor, 3-SKU coordination), the score should be 3-4, not 6.

• [dev] Rebuttal
  Rebuttal · fin · high/high

  Year 1 revenue $1M with breakeven month 18, assuming 70% subscription attach and $60-90 CAC → Both undefended assumptions. Furbo Nanny attach reportedly <30%; Peloton attach <50%. DTC pet-hardware CAC benchmarks $100-200. At 40% attach and $150 CAC, the fin brief's own sensitivities show breakeven slips past month 24 — beyond the seed runway. The Y1 $1M figure also requires 3.5K units shipped, which assumes first retail ship by month 6 — impossible given 8-12 week tooling + 8-12 week FCC + non-existent classifier dataset.

• [dev] Rebuttal
  Rebuttal · reg · high/medium

  Risk level 'medium' with FCC + UL certifications and ToS architecture sufficient to manage state privacy/biometric exposure → Continuous in-home camera doing pose classification plus always-on audio recording in two-party-consent states is high-risk, not medium. BIPA class actions have settled at $650M (Facebook), $92M (TikTok). Pose data may qualify as biometric identifier under IL/TX/WA statutes. Cloud inference path means data leaves the device, eliminating the 'on-device' defense. Risk level should be elevated to high; a single BIPA class certification kills the company.

Showing first 8 of 9 decisions.